TREACE MEDICAL CONCEPTS, INC. Q3 FY2026 earnings call

• Strategic Expansion: The company is expanding its addressable market by approximately $700 million through new product introductions, moving beyond its anchor position in bunion correction to become a comprehensive foot and ankle technology partner.
• Bunion Portfolio Adoption: Approximately 45% of Laplasty surgeons now use at least one of the three new bunion systems launched in Q3 2025 (Nanoplasty, Percoplasty, Speed MTP), up from 40% in Q2. There is significant cross-pollination, with ~30% of new customers acquired via these systems also adopting Laplasty products.
• Clinical Evidence: Strengthened clinical library with five-year data from the Align3D study showing low recurrence rates for Laplasty, plus positive results from Adductoplasty and Speed Plate studies.
• New Product Launches (2026): Fully launched SuperBite compression screws, HyperPlate XM fixation plates, VitaFuse bioactive glass grafts, and CartoBlaster rasps. These four products are estimated to expand US TAM by $400 million.
• Future Pipeline: Final preparations underway for the Q1 2027 commercial launch of the Laplasty Lightning platform and Intelliguide PSI expansion. Taylor Plasty system completed initial cases, with full commercialization expected in Q1 2027.
• Operational Efficiency: Year-to-date cash usage reduced by 53% ($9.7 million) compared to the same period in 2025. Cash, equivalents, and marketable securities totaled $39.8 million as of September 30, 2026.

The company reported total third-quarter revenue of $48.3 million, a decrease of 4% compared to the prior year period. This decline was primarily driven by a shift in revenue mix toward lower-priced minimally invasive products and a reduction in bunion procedure kit sales volume from stocking distributors. Excluding stocking distributor sales, bunion kit volume increased, and revenue grew mid-single digits. Gross margin improved to 79.5% from 79.1% in the prior year period. Total operating expenses decreased by $5.5 million (10%) to $49.9 million. Net loss narrowed by 23% to $12.6 million ($0.19 per share), and Adjusted EBITDA turned positive at $0.3 million, compared to a loss of $2.6 million in the prior year.

• Full Year 2026 Revenue: Narrowed guidance range to $206 million–$210 million (previously $204 million–$212 million). This represents a decline of 3% to 1% compared to full year 2025.
• Q4 Outlook: Management expects a return to revenue growth in the seasonally strong fourth quarter, driven by procedure volume increases and lapping ASP mix shifts from 2025 launches while benefiting from 2026 product introductions.
• Adjusted EBITDA: Updated expectation for a full-year 2026 loss in the range of $1 million to $2 million, an improvement from the $3.9 million loss in full year 2025.
• Cash Usage: Reiterated expectation of a ~50% reduction in cash usage for full year 2026 compared to full year 2025.

• ASP Mix Shift: Continued introduction of lower-priced minimally invasive products may pressure Average Selling Prices (ASPs) and revenue per case, although offset by higher-value complex midfoot/rearfoot procedures.
• Execution Risk: Managing the phasing of multiple new product launches during the busy bunion season carries execution risks; however, management believes the direct sales force can integrate these seamlessly due to existing customer relationships.
• Market Volume Trends: General commentary on slowing procedure volumes in the broader orthopedic market, though Treace has seen double-digit volume growth due to portfolio expansion.
• International Expansion: While international markets represent an opportunity, regulatory and logistical hurdles require time to navigate, and no material updates are expected immediately.

Q: Analyst asked about the ASP dynamic going forward as new products with lower ASPs are adopted versus high-complexity cases. / A: CEO stated that while MIS products carry lower ASPs, the robust portfolio includes high-reimbursed complex midfoot/rearfoot cases that balance this. He noted the gap between volume growth and revenue growth is narrowing, and the broad portfolio strategy benefits long-term positioning despite potential short-term ASP compression.

Q: Analyst asked about the sustainability of adoption rates for new bunion systems and whether they will plateau or continue growing. / A: CEO highlighted that nearly half of the 3,300 surgeon customers have adopted new systems, but there is significant room for growth. The goal is not just initial adoption but deep utilization (using 2-5 systems per surgeon) to make Treace a 'one-stop shop,' driving stickiness and repeat orders across the entire foot and ankle portfolio.

Q: Analyst asked why the upper end of the revenue guidance was lowered despite a sales beat and strong volume trends. / A: CFO explained that the Q3 beat was modest and driven by early bunion season and new product adoption, but underlying revenue growth excluding stocking distributors was only mid-single digits. They narrowed the range to ensure expectations are achievable and reflect visibility, confident in returning to growth in Q4 as stocking headwinds diminish.

Q: Analyst asked if the company plans to add sales headcount to support the expanding portfolio and how this impacts OpEx leverage. / A: CEO noted that reps efficiently sell additional technologies within existing cases without needing massive headcount increases, though modest incremental hiring continues. CFO added that most sales costs are variable/commission-based, aligning with revenue. He emphasized that despite flat/down revenue, the company has dramatically improved cash usage and EBITDA, indicating strong operating leverage.

Q: Analyst asked about the timeline and potential for international expansion given the now-broader portfolio. / A: CEO confirmed international is a real opportunity with demonstrated demand from visiting surgeons. However, entering these markets takes time due to regulatory and logistical complexities. Management will provide updates only when developments become material, indicating it is not an immediate near-term driver of financial results.